Acta Haematologica最新文献

{"title":"Real World Experience of Azacitidine + Venetoclax in Acute Myeloid Leukemia Rigorously Following Management Guidelines from Clinical Trial.","authors":"Bochra Sedaki, Alexandre Iat, Sami Benachour, Michael Loschi, Karine Risso, Ghada Abichou, Corinne Ferrero-Vacher, Neila De Pooter, Joy Mouanes-Abelin, Berengere Dadone-Montaudie, Thomas Cluzeau","doi":"10.1159/000548334","DOIUrl":"10.1159/000548334","url":null,"abstract":"<p><strong>Introduction: </strong>Azacitidine + venetoclax is a new standard of care for acute myeloid leukemia not eligible for intensive chemotherapy. This combination is associated with hematological toxicities and some drug interactions. Real-world studies have shown a decrease in results and outcomes when compared to the VIALE-A study.</p><p><strong>Methods: </strong>We report here our single-center experience using AZA + VEN, rigorously following management guidelines from the VIALE-A study, applied to a real-life population.</p><p><strong>Results: </strong>Forty-two AML patients were analyzed. The complete remission (CR)/CR with incomplete recovery (CRi)/MLFS rate was 73.8% after 1 cycle with 51% CR/CRi and 80.9% after 2 cycles. Median overall survival was 18 months (95% CI, 10.3-25.7). Our retrospective study showed that rigorous use of AZA + VEN in a real-world setting was associated with results close to clinical trial observations.</p><p><strong>Conclusion: </strong>We showed the need to rigorously follow AZA+VEN dosage but also toxicity guidelines and practice recommendations edited in the clinical trial even in the real world.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"493-497"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence in Haematologic Diagnostics: Current Applications and Future Perspectives.","authors":"Annatina Sarah Schnegg-Kaufmann, Ulrike Bacher, Alicia Rovó, Martin Andres, Gertrud Wiedemann, Naomi Porret, Bijan Moshaver, Nicolas Kaufmann, Joëlle Tchinda, Sara C Meyer, Anne Angelillo-Scherrer","doi":"10.1159/000548753","DOIUrl":"10.1159/000548753","url":null,"abstract":"<p><p><p>Background: Clinical researchers and laboratory specialists are striving to explore artificial intelligence (AI) to facilitate and optimize haematological diagnostics in response to the growing demand for more efficient and accurate diagnoses. Summary: This review summarizes current approaches integrating AI into blood and bone marrow cytomorphology, flow cytometry (FC), genetics, and haemostasis. Efforts include automated cell differentiation in peripheral blood and bone marrow aspirates, algorithms for identifying causes of anaemia, tools for rapid diagnosis of acute leukaemia, and other haematological entities. AI in FC may reduce subjectivity and variability, while in genomics, machine learning is increasingly implemented for processing high-throughput sequencing data and may enable automated detection of karyotypes in the future. In haemostasis, AI allows for automation in quality control, the establishment of personalized reference ranges, and potentially automated result interpretation. AI has, however, limitations such as cross-platform compatibility and often lacks sufficient validation. Ethical concerns include risks of bias and regulations are lagging behind the rapid developments. Key Messages: AI shows promise for automating and improving many steps in haematological diagnostics, though final interpretation still needs expert haematologists. </p>.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"413-426"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13645335/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145278637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case Series of SGLT2i Improving Hemoglobin in Adults with Myelodysplastic Syndrome.","authors":"Patricia Olar, Stephanie Lee, Michael Fralick","doi":"10.1159/000550197","DOIUrl":"10.1159/000550197","url":null,"abstract":"<p><strong>Introduction: </strong>The objective of our case series was to assess the change in hemoglobin for adults with myelodysplastic syndrome (MDS) started on a sodium glucose cotransporter 2 inhibitor (SGLT2i) for their diabetes, heart failure, or chronic kidney disease.</p><p><strong>Case presentation: </strong>Four patients with bone marrow biopsy confirmed low- or intermediate-risk MDS were referred for consideration of SGLT2i between July 2024 and December 2024. The patients were followed prospectively and had a repeat complete blood count at least 3 months after starting empagliflozin at 10 mg daily. The patients provided written consent for their results to be published. Median age was 78 years (range 76-82 years), 3 of the 4 patients were men, and the median baseline hemoglobin was 11.6 g/dL (IQR 9.3-12.8). Over a median duration of 4 months of taking empagliflozin, the median repeat hemoglobin was 12.8 g/dL (IQR 10.3-13.7).</p><p><strong>Conclusions: </strong>In our case series of 4 patients with MDS started on empagliflozin, we observed an increase in hemoglobin for all 4 patients. Larger studies are needed to assess whether the increase in hemoglobin is sufficiently robust and sustained to reduce a person's need for future red blood cell transfusion or other treatments for MDS.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"503-506"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145825589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hans-Based Cell of Origin Is Not of Prognostic Significance in Diffuse Large B-Cell Lymphoma Patients: A Retrospective Single-Center Study Conducted in 326 RCHOP-Treated Patients.","authors":"Marianthi Symeonidou, Stergios George Intzes, Konstantinos Zagoridis, Lazaros Karatisidis, Theodoros Mprotsis, Georgios Kanelis, Georgios Vrachiolias, Iliana Stamatiou, Zoe Bezirgiannidou, Bouse Malkots, Menelaos Papoutselis, Christoforos Roumpakis, Panagiotis Skendros, Panagiotis Tsikouras, Konstantinos Liapis, Ioannis Kotsianidis, Emmanouil Spanoudakis","doi":"10.1159/000549608","DOIUrl":"10.1159/000549608","url":null,"abstract":"<p><strong>Introduction: </strong>Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive lymphoma with dismal outcome after disease progression. Individual risk assessment can stratify patients into different treatment strategies.</p><p><strong>Methods: </strong>We retrospectively collected data from 326 DLBCL patients treated in a single center with RCHOP from 01/2000 to 06/2023. Immunohistochemistry by Han's algorithm was used to classify patients according to cell of origin (COO). The Kaplan-Meier estimator of survival and Cox regression analysis were used.</p><p><strong>Results: </strong>Time to progression (TTP) and overall survival (OS) were not different according to COO. Univariate analysis reveals International Prognostic Index (IPI), b2-microglobulin ≥3.5 mg/L, bulky disease, and abnormal LDH, but not Han's defined COO, as the strongest predictors for progression. IPI score in multivariate analysis was the only prognostic factor for OS and together with high b2-microglobulin levels were independently prognostic factors for TTP. Accordingly, b2-microglobulin ≥3.5 mg/L was an independent prognostic factor for progression both in GC (hazard ratio [HR] 0.249 [(95% CI: 0.087-0.649), p = 0.004] and non-GC DLBCL patients (HR 0.380 [95% CI: 0.177-0.813], p = 0.011).</p><p><strong>Conclusion: </strong>COO according to Hans index is not a significant prognostic factor for DLBCL patients, but b2-microglobulin ≥3.5 mg/L and IPI 2-5 in both GC and non-GC patients can predict individually a higher risk for progression.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"575-584"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145779728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minimal Clonal Plasma Cell Contamination of Peripheral Stem Cell Grafts Has an Adverse Prognostic Impact in Patients with Multiple Myeloma Undergoing Autologous Transplantation.","authors":"Yang Liu, Danyang Shao, Yingjun Chang, Yazhe Wang, Xuelin Dou, Nan Peng, Lei Wen, Fengrong Wang, Xiaojun Huang, Xiaodong Mo, Jin Lu","doi":"10.1159/000548496","DOIUrl":"10.1159/000548496","url":null,"abstract":"<p><strong>Introduction: </strong>The significance of autografts' contamination by clonal plasma cells on clinical outcome in newly diagnosed multiple myeloma (NDMM) remains controversial.</p><p><strong>Methods: </strong>We retrospectively reviewed the clinical and laboratory data of NDMM patients who underwent autologous stem cell transplantation (ASCT) and had received graft minimal residual disease (gMRD) examination by multi-color flow cytometry.</p><p><strong>Results: </strong>From January 2011 to December 2022, 250 NDMM patients with complete cytogenetic information, gMRD information, and who received ASCT as consolidation were enrolled. Multi-flow cytometry can achieve a median detection sensitivity of 0.004%, and gMRD positivity was 12.4% at a median level of 0.0160% (interquartile range, 0.0049%, 0.05394%). Its presence was correlated with response to induction treatment, with percentages of 2.65%, 12.94%, 28.89%, and 57.14% of patients achieving complete response, very good partial response, partial response, and minimal response/stable disease, respectively. gMRD (+) patients had a higher risk of not achieving bone marrow MRD negativity post-ASCT. After a median follow-up of 33.5 months for the whole cohort, patients in the gMRD (+) group had significantly worse progression-free survival (PFS) than those in the gMRD (-) group did (34.8 vs. 65.0 months, p = 0.001). Multivariable analysis revealed that gMRD (-) was independently predictive of better PFS (hazard ratio 0.464, 95% confidence interval: 0.274-0.785, p = 0.004). We found the significance of gMRD on PFS was in high-risk subgroups and in patients who achieved ≤ partial response prior to ASCT.</p><p><strong>Conclusions: </strong>In conclusion, gMRD (+) was an independent risk factor for inferior progression-free survival, with the impact primarily affecting high-risk groups and patients who achieved ≤ partial response before ASCT.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"541-552"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145547464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis and Management of Philadelphia-Like Acute Lymphoblastic Leukemia in Adults.","authors":"Hoda Pourhassan, Winston Y Lee, Marc Schwartz, Vinod Pullarkat, Ibrahim Aldoss","doi":"10.1159/000549216","DOIUrl":"10.1159/000549216","url":null,"abstract":"<p><strong>Background: </strong>The entity of Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL) accounts for approximately 20-30% of newly diagnosed adults with B-cell ALL cases in the USA. Compared to other B-cell subtypes, Ph-like ALL is associated with overall poor prognosis and inferior outcomes with high measurable residual disease rates following induction therapy, increased risk of treatment failure and relapse, as well as short event-free and overall survival.</p><p><strong>Summary: </strong>Here we aim to highlight Ph-like ALL genetic subtypes and methods of genomic profiling for diagnosis and disease prognostication and to summarize current management approaches for frontline treatment including multiagent chemotherapy, immunotherapy, tyrosine kinase and small molecule inhibitors, and the role of allogeneic stem cell transplantation.</p><p><strong>Key messages: </strong>Despite the improvement in the treatment outcomes of adult patients with newly diagnosed B-cell ALL, patients with Ph-like ALL continue to do poorly with standard therapy. Thus, tailored therapeutic studies are indeed warranted to refine frontline treatment approaches and to improve outcomes for patients with Ph-like ALL.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"48-60"},"PeriodicalIF":1.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145375577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study.","authors":"Haifa Kathrin Al-Ali, Paola Guglielmelli, Claire N Harrison, Ruben A Mesa, J E Hamer-Maansson, Evan Braunstein, Vikas Gupta","doi":"10.1159/000546585","DOIUrl":"10.1159/000546585","url":null,"abstract":"<p><p><p>Introduction: Anemia can influence decisions regarding initiation, dosing, and discontinuation of Janus kinase inhibitor therapy for myelofibrosis. We evaluated the impact of new-onset or worsening anemia following ruxolitinib initiation on spleen response, symptom severity, and overall survival in patients with myelofibrosis.</p><p><strong>Methods: </strong>This post hoc analysis used data from all patients enrolled in the phase 3b JUMP trial. Outcomes were stratified by presence or absence of new-onset or worsening anemia following ruxolitinib initiation, defined as hemoglobin decrease ≥15 g/L from baseline and hemoglobin <100 g/L (female)/<110 g/L (male) at Week 12, new transfusion requirement post-baseline until Week 12 (for baseline non-transfusion-dependent patients), or ≥50% increase from baseline in red blood cell transfusions through Week 12.</p><p><strong>Results: </strong>Overall, 2,233 patients were included; 52.9% developed new-onset or worsening anemia up to Week 12. Ruxolitinib was associated with improvements in spleen length and myelofibrosis symptoms, regardless of the presence or absence of new-onset or worsening anemia or baseline anemia status. No differences in spleen response or overall survival were observed between patients with versus without new-onset or worsening anemia, regardless of baseline anemia status.</p><p><strong>Conclusions: </strong>These results support the use of ruxolitinib in patients with myelofibrosis, regardless of baseline anemia or development of treatment-related anemia. </p>.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"363-372"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Role of Circular RNAs in Mantle Cell Lymphoma: A Competing Endogenous RNA Network Analysis.","authors":"Chen-Xuan Huang, Xu-Dong Ma, Wei Zhuang, Yong Zou","doi":"10.1159/000547908","DOIUrl":"10.1159/000547908","url":null,"abstract":"<p><strong>Introduction: </strong>This study evaluated the prognostic role of circular RNAs (circRNAs) in individuals diagnosed with mantle cell lymphoma (MCL), using the framework of the competing endogenous RNA (ceRNA) network model.</p><p><strong>Methods: </strong>Differentially expressed circRNAs were identified from the GSE159808 dataset, and differentially expressed messenger RNAs (mRNAs) were extracted from GSE32018. Corresponding microRNAs (miRNAs) were retrieved to construct a ceRNA regulatory network relevant to MCL. Functional enrichment analysis and survival analysis were performed on 35 mRNAs incorporated in the ceRNA network to identify transcripts associated with survival outcomes in MCL. A prognostically relevant ceRNA subnetwork was then constructed based on these results.</p><p><strong>Results: </strong>Thirteen circRNAs (9 upregulated, 4 downregulated) and 457 differentially expressed mRNAs were identified. The initial ceRNA network included 11 circRNAs, 40 miRNAs, and 35 mRNAs. Gene Ontology analysis indicated enrichment in pathways related to dentin-containing tooth development, the plasma membrane signaling receptor complex, and growth factor receptor binding. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis demonstrated significant involvement in the B-cell receptor signaling pathway, Fc gamma (Fcγ) receptor-mediated phagocytosis, and the Wnt signaling pathway. Survival analysis identified six mRNAs significantly associated with overall survival in individuals with MCL. These results were used to derive a refined prognostic ceRNA network consisting of 6 mRNAs, 7 miRNAs, and 6 circRNAs.</p><p><strong>Conclusion: </strong>CircRNAs may regulate MCL prognosis by modulating miRNA-mRNA interactions within the ceRNA network. These findings suggest a regulatory mechanism by which circRNAs contribute to molecular pathways influencing disease progression and survival in MCL.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"507-521"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146091888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"International Prognostic Scoring System, Revised International Prognostic Scoring System, and Molecular International Prognostic Scoring System Had No Identical Prognostic Power Depending on Treatment in Myelodysplastic Syndromes.","authors":"Ghada Abichou, Michael Loschi, Rinzine Sammut, Bochra Sedaki, Sami Benachour, Caroline Fileni, Corinne Ferrero-Vacher, Neila De Pooter, Joy Mouanes-Abelin, Berengere Dadone-Montaudie, Thomas Cluzeau","doi":"10.1159/000549858","DOIUrl":"10.1159/000549858","url":null,"abstract":"<p><strong>Introduction: </strong>The Revised International Prognostic Scoring System (IPSS-R) has long been the standard prognostic tool in the management of myelodysplastic syndromes (MDS). Recently, a new clinical-molecular prognostic model, the IPSS-M, was introduced. This model integrates MDS-related gene mutations and offers improved accuracy and precision in predicting patient outcomes and survival. In this study, we compare the prognostic value and predictive capacity of these prognostic scores across different treatment groups.</p><p><strong>Methods: </strong>IPSS, IPSS-R, and IPSS-M scores were calculated at diagnosis for all eligible MDS patients in this cohort. Sankey diagrams were generated to visually compare the risk stratification across the three scoring systems.</p><p><strong>Results: </strong>A total of 394 patients were included in this retrospective analysis. During the course of the disease, 59.1% required treatment, with 38.1% (150 patients) receiving erythropoiesis-stimulating agents (ESA) and 19.0% (75 patients) treated with hypomethylating agents (HMA). The IPSS-M was calculated for 281 patients and reclassified 41.9% of cases: 20.3% (n = 57) were upstaged and 21.7% (n = 61) were downstaged. All three scoring systems demonstrated significant stratification of overall survival (OS) in the global cohort (p < 0.001 for IPSS, IPSS-R, and IPSS-M). Notably, IPSS failed to predict OS in patients treated with azacitidine, and none of the scores successfully predicted OS in patients treated with ESA.</p><p><strong>Conclusion: </strong>The IPSS-M effectively reclassified 41.9% of patients, upstaging 20.2% and downstaging 21.7%. However, our analysis found that none of the prognostic scores effectively predicted outcomes for ESA-treated patients. Further studies are needed to assess whether the predictive value of these scoring systems is influenced by the specific treatment modalities used.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"585-593"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146040074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acquired FX Deficiency in Multiple Myeloma without Concomitant Amyloidosis: A Rare Case Report.","authors":"Roi Gat, Svetlana Trestman, Ilya Kirgner","doi":"10.1159/000545479","DOIUrl":"10.1159/000545479","url":null,"abstract":"<p><p><p>Introduction: Acquired factor X (FX) deficiency is a rare coagulopathy. Occurrences in plasma cell dyscrasias (PCDs) independent of amyloid light-chain amyloidosis are exceedingly rare. Case Presentation: This case report presents a rare occurrence of acquired FX deficiency in a patient with multiple myeloma (MM) without concomitant amyloidosis. The patient, a 64-year-old male with prior diagnosis of smoldering MM, presented with abdominal pain and chronic bloody diarrheas and was diagnosed with absolute FX deficiency. Despite initial suspicion of amyloidosis, subsequent investigations ruled out its presence. Treatment with anti-myeloma therapy and supportive measures resulted in the normalization of coagulation parameters. Conclusion: This case underscores the importance of considering acquired FX deficiency in PCD patients presenting with coagulopathy even in the absence of amyloidosis. </p>.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"228-232"},"PeriodicalIF":1.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12060824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}